Pacira BioSciences Inc (PCRX)
17.38
+0.35
(+2.06%)
USD |
NASDAQ |
Nov 21, 16:00
17.40
+0.02
(+0.09%)
After-Hours: 20:00
Pacira BioSciences Enterprise Value: 936.04M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 936.04M |
| November 20, 2024 | 919.88M |
| November 19, 2024 | 906.02M |
| November 18, 2024 | 901.87M |
| November 15, 2024 | 900.02M |
| November 14, 2024 | 889.40M |
| November 13, 2024 | 893.10M |
| November 12, 2024 | 909.26M |
| November 11, 2024 | 941.58M |
| November 08, 2024 | 929.57M |
| November 07, 2024 | 950.81M |
| November 06, 2024 | 949.43M |
| November 05, 2024 | 931.42M |
| November 04, 2024 | 893.10M |
| November 01, 2024 | 898.64M |
| October 31, 2024 | 899.61M |
| October 30, 2024 | 912.07M |
| October 29, 2024 | 926.37M |
| October 28, 2024 | 924.06M |
| October 25, 2024 | 910.22M |
| October 24, 2024 | 918.99M |
| October 23, 2024 | 935.60M |
| October 22, 2024 | 947.14M |
| October 21, 2024 | 933.29M |
| October 18, 2024 | 940.68M |
| Date | Value |
|---|---|
| October 17, 2024 | 915.76M |
| October 16, 2024 | 900.99M |
| October 15, 2024 | 903.76M |
| October 14, 2024 | 886.68M |
| October 11, 2024 | 882.07M |
| October 10, 2024 | 849.30M |
| October 09, 2024 | 852.53M |
| October 08, 2024 | 856.23M |
| October 07, 2024 | 871.46M |
| October 04, 2024 | 895.68M |
| October 03, 2024 | 866.84M |
| October 02, 2024 | 850.23M |
| October 01, 2024 | 839.61M |
| September 30, 2024 | 828.08M |
| September 27, 2024 | 855.76M |
| September 26, 2024 | 846.07M |
| September 25, 2024 | 826.70M |
| September 24, 2024 | 842.84M |
| September 23, 2024 | 843.77M |
| September 20, 2024 | 855.30M |
| September 19, 2024 | 862.68M |
| September 18, 2024 | 860.83M |
| September 17, 2024 | 846.76M |
| September 16, 2024 | 807.33M |
| September 13, 2024 | 789.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
724.76M
Minimum
Aug 09 2024
4.150B
Maximum
Apr 08 2022
2.242B
Average
2.258B
Median
Sep 14 2021
Enterprise Value Benchmarks
| Cyclo Therapeutics Inc | 31.36M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -143.47M |
| Revenue (Quarterly) | 168.57M |
| Total Expenses (Quarterly) | 146.62M |
| EPS Diluted (Quarterly) | -3.11 |
| Gross Profit Margin (Quarterly) | 76.95% |
| Profit Margin (Quarterly) | -85.11% |
| Earnings Yield | -11.56% |
| Operating Earnings Yield | 10.78% |
| Normalized Earnings Yield | 4.102 |